Weining Ma

1.2k total citations
25 papers, 887 citations indexed

About

Weining Ma is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Weining Ma has authored 25 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Reproductive Medicine. Recurrent topics in Weining Ma's work include Ovarian cancer diagnosis and treatment (7 papers), HER2/EGFR in Cancer Research (6 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Weining Ma is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), HER2/EGFR in Cancer Research (6 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Weining Ma collaborates with scholars based in United States, China and France. Weining Ma's co-authors include Shanu Modi, Alison L. Hannah, Clifford A. Hudis, Alison Stopeck, David B. Solit, Larry Norton, Neal Rosen, Maura N. Dickler, Sujata Patil and Steven Sugarman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Weining Ma

24 papers receiving 866 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weining Ma United States	13	524	301	152	145	84	25	887
Martina Rahmeh Germany	13	476 0.9×	677 2.2×	276 1.8×	96 0.7×	20 0.2×	22	1.2k
Olaf Hellwinkel Germany	17	576 1.1×	221 0.7×	145 1.0×	111 0.8×	60 0.7×	37	1.1k
Annemarie Larkin Ireland	18	477 0.9×	318 1.1×	60 0.4×	72 0.5×	91 1.1×	32	770
Hima Patel United States	12	383 0.7×	277 0.9×	86 0.6×	78 0.5×	41 0.5×	20	682
B Soehnlen United States	11	582 1.1×	513 1.7×	120 0.8×	125 0.9×	84 1.0×	15	1.2k
Andrew Dorr United States	16	737 1.4×	356 1.2×	44 0.3×	64 0.4×	23 0.3×	37	1.0k
Sharon Glaysher United Kingdom	16	324 0.6×	286 1.0×	27 0.2×	54 0.4×	57 0.7×	30	690
Naomi Laing United States	18	367 0.7×	454 1.5×	40 0.3×	72 0.5×	85 1.0×	31	804
Robert Kubiak Poland	18	553 1.1×	206 0.7×	116 0.8×	144 1.0×	48 0.6×	77	1.1k

Countries citing papers authored by Weining Ma

Since Specialization

Citations

This map shows the geographic impact of Weining Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weining Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weining Ma more than expected).

Fields of papers citing papers by Weining Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weining Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weining Ma. The network helps show where Weining Ma may publish in the future.

Co-authorship network of co-authors of Weining Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Weining Ma. A scholar is included among the top collaborators of Weining Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weining Ma. Weining Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Weining, Thais Basili, Nadeem R. Abu‐Rustum, et al.. (2024). ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high ( MSI ‐H) molecular subtype. Molecular Oncology. 18(10). 2356–2368. 2 indexed citations

Shen, Sherry, Weining Ma, David N. Brown, et al.. (2023). HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology. 36(11). 100299–100299. 12 indexed citations

Ma, Weining, Sushmita Gordhandas, Qin Zhou, et al.. (2023). Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecologic Oncology. 178. 27–35. 7 indexed citations

Andrieu, Pamela Causa, Ines Nikolovski, Krishna Juluru, et al.. (2023). Synoptic Reporting for Pretreatment CT Examination in Patients With Advanced Ovarian Cancer: Impact on Documentation of Disease Sites and Physician Satisfaction. American Journal of Roentgenology. 221(6). 760–772. 3 indexed citations

Li, Xinyu, Weining Ma, Lixin Su, et al.. (2022). Association of Angiogenesis Gene Expression With Cancer Prognosis and Immunotherapy Efficacy. Frontiers in Cell and Developmental Biology. 10. 805507–805507. 6 indexed citations

Rubinstein, Maria M., Priyanka Narayan, Qin Zhou, et al.. (2021). Bevacizumab in advanced endometrial cancer. Gynecologic Oncology. 161(3). 720–726. 12 indexed citations

Filippova, Olga T., Renee A. Cowan, Yulia Lakhman, et al.. (2020). A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology. 158(3). 608–613. 24 indexed citations

Li, Wei, Vishnu Priya Veeraraghavan, & Weining Ma. (2020). Effects of Boldine on Antioxidants and Allied Inflammatory Markers in Mouse Models of Asthma. Journal of Environmental Pathology Toxicology and Oncology. 39(3). 225–234. 7 indexed citations

Ma, Weining, Debra Sarasohn, Junting Zheng, Hebert Alberto Vargas, & Ariadne M. Bach. (2017). Causes of Avascular Hypoechoic Testicular Lesions Detected at Scrotal Ultrasound: Can They Be Considered Benign?. American Journal of Roentgenology. 209(1). 110–115. 13 indexed citations

10.

Mantha, Simon, Debra Sarasohn, Weining Ma, et al.. (2015). Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance. American Journal of Obstetrics and Gynecology. 213(2). 208.e1–208.e4. 16 indexed citations

11.

Pannu, Harpreet K., Weining Ma, Emily C. Zabor, et al.. (2013). Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies. ISRN Obstetrics and Gynecology. 2013. 1–8. 5 indexed citations

12.

Jhaveri, Komal, Kathy D. Miller, Lee S. Rosen, et al.. (2012). A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research. 18(18). 5090–5098. 49 indexed citations

13.

Grisham, Rachel N., David M. Hyman, Weining Ma, et al.. (2012). Gemcitabine for Advanced Endometrial Cancer. International Journal of Gynecological Cancer. 22(5). 807–811. 10 indexed citations

14.

Modi, Shanu, Alison Stopeck, Hannah Linden, et al.. (2011). HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research. 17(15). 5132–5139. 328 indexed citations

15.

Dickler, Maura N., Simone Di Franco, Alison Stopeck, et al.. (2009). Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC).. Cancer Research. 69(2_Supplement). 3133–3133. 12 indexed citations

16.

Rugo, Hope S., Sandra Franco, P.N. Munster, et al.. (2008). A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1042–1042. 16 indexed citations

17.

Ma, Weining, Joseph M. Herman, Daniel A. Laheru, et al.. (2008). A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa). International Journal of Radiation Oncology*Biology*Physics. 72(1). S127–S127. 1 indexed citations

18.

Modi, Shanu, Alison Stopeck, Michael S. Gordon, et al.. (2007). Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology. 25(34). 5410–5417. 266 indexed citations

19.

Modi, Shanu, A. Stopeck, Michael S. Gordon, et al.. (2006). Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). Journal of Clinical Oncology. 24(18_suppl). 501–501. 8 indexed citations

20.

Lobb, Roy R., William M. Abraham, Linda C. Burkly, et al.. (1996). Pathophysiologic Role of α4 Integrins in the Lung. Annals of the New York Academy of Sciences. 796(1). 113–123. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact